Unlocking Multiple Sclerosis Genetics: From Disease Risk to Disability Progression
Sahi and colleagues review a central challenge in multiple sclerosis (MS): why some individuals experience relatively mild disease while others develop substantial disability despite sharing the same diagnostic label. The article argues that MS genetics must be understood across two related but distinct domains: susceptibility, meaning the likelihood of developing MS, and severity, meaning the biological and clinical forces that shape long-term disability. This distinction is important because MS is not a classically inherited disorder; rather, it is a complex disease shaped by many common genetic variants, environmental exposures, immune mechanisms, neurodegeneration, and time-dependent pathological change.
Susceptibility Genetics: The Immune System at the Forefront
The strongest and most historically important MS susceptibility signal lies in the HLA region, particularly HLA-DRB1*1501, which has been associated with increased MS risk and earlier disease onset. Genome-wide association studies have since expanded this picture substantially, identifying more than 230 susceptibility variants, many of which implicate peripheral immune cells and immune-mediated inflammatory pathways. However, the authors emphasize that these variants are neither necessary nor sufficient to cause MS. Most people carry numerous risk alleles but never develop the disease, demonstrating that genetic susceptibility operates probabilistically rather than deterministically.
From Risk to Activity: Why HLA-DRB1*1501 Is Not the Whole Story
Although HLA-DRB1*1501 remains the dominant MS-risk allele, its relationship with disease severity is more complex than its relationship with susceptibility. The review summarizes evidence that this allele is associated with inflammatory disease activity, including greater white matter lesion burden, lesion accrual, and relapse activity in longitudinal clinically isolated syndrome cohorts. Yet the same studies do not consistently show a direct association with long-term disability or conversion to secondary progressive MS. This suggests that genes promoting inflammatory activity early in disease may not be the same genes that drive later neurodegeneration and irreversible disability.
Severity Genetics: The Emergence of rs10191329
A major advance highlighted in the article is the identification of rs10191329 near the DYSF-ZNF638 locus as the first genome-wide significant variant associated with age-related MS severity. This discovery shifted attention from immune susceptibility toward CNS resilience, neurodegeneration, and repair. In large collaborative cohorts, rs10191329 was associated with worse age-related disability, faster disability progression, increased risk of confirmed disability worsening, and shorter time to needing walking assistance. Pathological studies further linked rs10191329 risk homozygosity with more brainstem and cortical lesions, neuroaxonal injury, chronic inflammation, and higher neurofilament levels, strengthening the argument that MS severity may have a partly distinct CNS-centered genetic architecture.
Why Replication Has Been Difficult
The article carefully explains why replication of MS severity variants has been challenging. Severity studies often differ in sample size, disease duration, treatment exposure, ancestry, clinical outcome definitions, and statistical modeling. Measures such as the Expanded Disability Status Scale, age-related MS severity score, and MS severity scale are useful but imperfect because they are strongly weighted toward physical disability and ambulation. Some studies may capture inflammatory relapse-associated worsening, whereas others may capture progression independent of relapse activity. These methodological differences can obscure true biological signals, especially when genetic effects are modest and require very large cohorts for reliable detection.
Looking Beneath the Surface of Disability
One of the article’s most important scientific messages is that MS severity cannot be reduced to a single disability score. Disability arises from multiple mechanisms, including acute inflammation, chronic active lesions, cortical pathology, brain atrophy, neuroaxonal loss, impaired remyelination, and reduced CNS reserve. The authors therefore argue for deeper phenotyping using MRI biomarkers, cognitive measures, upper-limb assessments, patient-reported outcomes, and potentially wearable technologies. Such multidimensional phenotypes may reveal domain-specific genetic effects that conventional disability scales miss, especially in progressive MS, where cognition, gray matter pathology, and neurodegeneration may be more informative than relapse frequency alone.
Toward Personalized Prognosis and Progressive MS Therapeutics
The broader implication of the review is that MS genetics may eventually support clinically useful prognostic models and identify novel therapeutic targets, particularly for progressive disease. Achieving this goal will require larger ancestrally diverse cohorts, rare-variant analyses, pathway-level approaches, better causal inference, and deeper study of gene-environment and epigenetic interactions. The article is cautious but optimistic: susceptibility genetics has already clarified the immune basis of MS onset, while severity genetics is beginning to illuminate CNS mechanisms that govern disability accumulation. The next scientific challenge is to translate these group-level discoveries into individualized prediction and mechanism-based interventions for people living with MS.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Sahi, N., Ciccarelli, O., Houlden, H., & Chard, D. T. (2025). Unlocking multiple sclerosis genetics: from susceptibility to severity. Neurology, 105(8), e214141.
